Evidence map›Paper›PMID 28154958›Full record

ArticleHeart and vessels2017

Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.

Ryunosuke Okuyama, Junnichi Ishii, Hiroshi Takahashi, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Sadako Motoyama, Shigeru Matsui, Hiroyuki Naruse and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. BEEAFJournal of the American Heart Association · 2024
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Ryunosuke OkuyamaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Junnichi IshiiDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan. jishii@fujita-hu.ac.jp.
Hiroshi TakahashiDivision of Statistics, Fujita Health University School of Medicine, Toyoake, Japan.
Hideki KawaiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Takashi MuramatsuDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Masahide HaradaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Akira YamadaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Sadako MotoyamaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Shigeru MatsuiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Hiroyuki NaruseDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Masayoshi SaraiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Midori HasegawaDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Eiichi WatanabeDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Atsushi SuzukiDepartment of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake, Japan.
Mutsuharu HayashiDepartment of Cardiology, Banbuntane Houtokukai Hospital, Nagoya, Japan.
Hideo IzawaDepartment of Cardiology, Banbuntane Houtokukai Hospital, Nagoya, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Yukio OzakiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan.
Fujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Additional risk stratification may provide more aggressive and focalized preventive treatment to high-risk hypertensive patients according to the Japanese hypertension guidelines. We prospectively investigated the predictive value of high-sensitivity troponin I (hsTnI), both independently and in combination with N-terminal pro-B-type natriuretic peptide (NT-proBNP), for incident heart failure (HF) in high-risk hypertensive patients with preserved left ventricular ejection fraction (LVEF). Baseline hsTnI and NT-proBNP levels and echocardiography data were obtained for 493 Japanese hypertensive outpatients (mean age, 68.5 years) with LVEF ≥ 50%, no symptomatic HF, and at least one of the following comorbidities: stage 3-4 chronic kidney disease, diabetes mellitus, and stable coronary artery disease. During a mean follow-up period of 86.1 months, 44 HF admissions occurred, including 31 for HF with preserved ejection fraction (HFpEF) and 13 for HF with reduced ejection fraction (HFrEF; LVEF <50%). Both hsTnI (p < 0.01) and NT-proBNP (p < 0.005) levels were significant independent predictors of HF admission. Furthermore, when the patients were stratified into 4 groups according to increased hsTnI (≥highest tertile value of 10.6 pg/ml) and/or increased NT-proBNP (≥highest tertile value of 239.7 pg/ml), the adjusted relative risks for patients with increased levels of both biomarkers versus neither biomarker were 13.5 for HF admission (p < 0.0001), 9.45 for HFpEF (p = 0.0009), and 23.2 for HFrEF (p = 0.003). Finally, the combined use of hsTnI and NT-proBNP enhanced the C-index (p < 0.05), net reclassification improvement (p = 0.0001), and integrated discrimination improvement (p < 0.05) to a greater extent than that of any single biomarker. The combination of hsTnI and NT-proBNP, which are individually independently predictive of HF admission, could improve predictions of incident HF in high-risk hypertensive patients but could not predict future HF phenotypes.

Indexed as

HospitalizationAgedAged, 80 and overBiomarkersEchocardiography, DopplerFemaleHeart FailureHumansHypertensionJapanKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainProportional Hazards ModelsBiomarkersNatriuretic Peptide, BrainTroponin IHeart failure admissionHigh-sensitivity troponin IHypertensionN-terminal pro-B-type natriuretic peptide

Identifiers

PMID28154958
OpenAlexW2585504042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.